Harmony Biosciences Holdings, Inc. — Form 8-K Summary
Business Context and Reporting Period
Harmony Biosciences Holdings, Inc. filed a Form 8-K dated May 29, 2024, reporting the results of its 2024 Annual Meeting of Stockholders. The filing addresses corporate governance matters under Item 5.07 and does not report quarterly or annual operating results.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes and Meeting Results
- Quorum: 40,712,810 shares were represented in person or by proxy.
- Director elections: Jeffrey S. Aronin, R. Mark Graf, and Jeffrey M. Dayno, M.D. were each elected as Class I directors to serve until the 2027 Annual Meeting and until their successors are elected and qualified.
- Votes for the nominees: Aronin received 18,340,092; Graf received 18,542,554; and Dayno received 20,588,496.
- Auditor ratification: Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Auditor vote: 40,204,856 shares voted for, 495,232 against, and 12,722 abstained.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no management guidance, financial outlook, risk-factor updates, contingencies, or unusual financial items. Broker non-votes for each director nominee totaled 11,367,490.
Investor Verification Checklist
- Verify the elected Class I directors and their terms through the company’s proxy statement or subsequent corporate governance disclosures.
- Confirm Deloitte & Touche LLP’s appointment and review future filings for any changes in the independent auditor relationship.
- Review the company’s periodic reports for financial performance, liquidity, debt, guidance, and material risk information not included in this 8-K.